Unicycive Therapeutics, Inc. Common Stock (UNCY)
Unicycive Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for liver and kidney diseases. The company's portfolio includes innovative therapies aimed at addressing unmet medical needs in chronic liver and renal conditions. Unicycive aims to leverage its expertise in drug development to improve patient outcomes.
Company News
Rosen Law Firm alerts Unicycive Therapeutics investors about a potential securities fraud lawsuit, claiming the company made false statements about FDA manufacturing compliance and drug application prospects during the period of March 29, 2024 to June 27, 2025.
Unicycive Therapeutics reported a Q2 2025 net loss of $0.52 per share, with reduced R&D expenses and ongoing regulatory challenges for its lead kidney disease treatment oxylanthanum carbonate. The company received a Complete Response Letter from the FDA and is seeking a meeting to resolve manufacturing concerns.
The article discusses several stocks to watch on Monday, including Greenbrier Companies, Nature Wood Group, Fortress Biotech, Sonic Automotive, and Unicycive Therapeutics.
Unicycive (UNCY) rises after the encouraging progress in the late-stage development of its lead candidate, OLC, for the hyperphosphatemia indication. The NDA submission is expected around mid-2024.
Use these tips for analyzing penny stocks after a market crash The post Analyzing Penny Stocks After a Market Crash, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.